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Abstract
To address the question of how cells respond to the possible Ca2+ toxicity caused by the release of
Ca2+ into the cytoplasm by LCP nanoparticles, a series of in vitro and in vivo studies using Ca2+
pump inhibitors were conducted. The results indicated that two major Ca2+ pumps on the plasma
membrane and the mitochondrial membrane, respectively, were able to rapidly respond to the
elevated cytosolic Ca2+ concentration and prevent Ca2+-induced apoptosis or necrosis. However,
exposure to specific inhibitors of calcium pumps would cause LCP-treated H460 cells to undergo
necrosis both in vitro and in vivo. These results demonstrated that the Ca2+ delivered by LCP was
not toxic to cells when the cells contain functional Ca2+ pumps.
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INTRODUCTION
The LCP (Lipid/Calcium/Phosphate) nanoparticles (NPs) are a versatile formulation for in
vivo siRNA, chemical drug (gemcitabine phosphates, manuscripts in submission), and
cDNA plasmid delivery. There were two generations of LCP NPs.1–4 The first generation
(LCP-I) was a proof-of-concept formulation showing the feasibility of utilizing
microemulsion technology to create calcium-phosphate (CaP) nanoprecipitate cores that
entrap siRNA in a reverse microemulsion system. After collecting the CaP-siRNA cores,
sodium citrate was used to stabilize them and to provide a negative surface charge. Cationic
liposomes were then added, forming a lipid bilayer coating around the cores, to which
DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-poly(ethylene
glycol)2000) could be post-inserted for protection of the surface. However, the preparation
of the LCP-I was limited by the inclusion of an un-scalable column chromatography step for
purification. The formulation was additionally limited by the fact that only cationic lipids
could be incorporated into the lipid coating.
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The LCP-II formulation was an improvement to the preparation of LCP-I through the
introduction of dioleoylphosphatydic acid (DOPA) as the inner leaflet lipid. Utilizing the
microemulsion technology in a similar manner as in LCP-I preparation, the CaP core of the
LCP-II was coated with a single DOPA layer. The phosphate head group of DOPA provides
a strong binding interaction with the CaP core and prevents the core from aggregation. The
acyl chain of DOPA also provided a hydrophobic surface that enabled an extensive wash
with ethanol and storage in CHCl3. Additionally, the core could then be coated with the
lipids of choice as an outer leaflet to form an asymmetric lipid bilayer. For example, the
cationic 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) lipid was often used as an
outer leaflet due to its ability to destabilize the endosomes. Neutral
dioleoylphosphatidylcholine (DOPC) with 20% DSPE-PEG on the other hand, provides
prolonged circulation time, and was used for tumor and lymph node imaging after
intravenous injection (manuscript in submission).
The well-established method of calcium phosphate transfection for plasmid DNA delivery5
is similar to the process through which the CaP cores in LCP NPs precipitate with siRNA
(or DNA). Furthermore, the CaP-siRNA or CaP-DNA co-precipitates are acid sensitive.
After cellular internalization, the co-precipitates will dissolve in the acidic endosomal
environment to induce an osmotic lysis and release the trapped siRNA (or DNA). This
mechanism was designed to improve the release of siRNA into the cytoplasm.1 This CaP
dissolution and endosome escape was demonstrated further using a calcium sensing dye,
Fura-2, to visualize the elevated cytoplasmic calcium concentrations.4
Compared to the LPD (Lipid/Protamine/DNA) formulation that was previously developed in
our lab, the gene silencing activities of LCP-I and LCP-II were significantly improved.
Luciferase silencing experiments in vitro showed that the IC50 was 5 nM for LCP-II, 50 nM
for LCP-I, and 200 nM for LPD. The gene silencing effect in vivo demonstrated in an NCI-
H460 xenograft model expressing luciferase showed that when a dose of 1.2 mg/kg siRNA
is delivered in LCP-II, LCP-I, or LPD formulations, the knockdown of luciferase in vivo was
~65, ~50, and ~25% efficient, respectively.1–4
Under physiological conditions, the extracellular Ca2+ concentration is ~1.2 mM and the
cytosolic concentration is ~0.1 μM. The cytosolic Ca2+ concentration is associated with
almost all cellular signaling and metabolic events, including cell growth and proliferation,
cellular motility, contractility, and neuronal transmission.6,7 Ca2+ also plays important roles
in regulating several enzyme activities and ion channels.8,9 Low to moderate elevation of the
Ca2+ concentration (0.2~0.4 μM) triggers apoptosis and higher concentrations of Ca2+ (>1
μM) are associated with necrosis.10–14 For these reasons, it is necessary to address if the
Ca2+ delivered by LCP is toxic to cells.
A low cytosolic concentration of Ca2+ is carefully maintained by several Ca2+ pumps on
plasma membrane, mitochondria, and endoplasmic reticulum (ER). Plasma membrane Ca2+
ATPase (PMCA) consumes ATP to extrude cellular Ca2+ with a high affinity, therefore
playing a major role in Ca2+ homeostasis and signaling. Inside of the cell, Ca2+ is stored
within the mitochondria and ER. When there is an inward flux of Ca2+, the mitochondrial
calcium uniporter (MCU) should be the one to initiate the lowering of cytoplasmic Ca2+
with a fast speed. PMCA, although with a slower speed, is the one eventually responsible for
lowering the cytoplasmic Ca2+ to resting homeostasis. The SERCA (sarco/endoplasmic
reticulum Ca2+-ATPase) on the ER, however, is not likely to take up Ca2+ due to the fact
that ER is already replete with Ca2+.15 To evaluate the role of SERCA when dosing the cells
with LCP, we have tested thapsigargin (a SERCA inhibitor) in cells treated with LCP. No
obvious LCP toxicity enhancement was observed when H460 cells were treated with LCP
and thapsigargin, indicating SERCA was not significantly involved in the homeostasis in
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this case (supplement figure 1). Based on the known calcium homeostasis mechanism and
our results with thaspsigargin, we hypothesized that when cells take up LCP and release
Ca2+ into the cytoplasm, Ca2+ pumps on the plasma membrane and the mitochondria, but
not the one on ER, will rapidly respond to the elevated cytosolic Ca2+ concentration and
prevent the cells from Ca2+ induced apoptosis or necrosis.
LCP-II with DOTAP/Cholesterol as an outer leaflet coating was prepared for the in vitro
study using the protocol (manuscript in submission) slightly modified from the original
one.1 Briefly, two reverse water-in-oil emulsions containing CaCl2 and Na2HPO4 were
mixed to form CaP nanoprecipitate which was stabilized by DOPA. After washing by
centrifugation, additional lipids containing DOTAP/Cholesterol were added to complete the
assembly of NPs. The prepared nanoparticles were ~25 nm in diameter and their zeta-
potentials were ~50 mV.
Fura-2, a ratiometric fluorescent dye that is sensitive to Ca2+, was used to study our
hypothesis.4 Fura-2 was the first widely-used calcium indicator, and remains very popular
especially in the neuroscience field. Free Fura-2 that is not bound to Ca2+ has a peak in the
excitation wavelength at 380 nm. Upon binding with Ca2+, there is a blue-shift in the
excitation peak, to 340 nm. The emission wavelength remains unchanged at 510 nm.
To examine our hypothesis we chose two specific Ca2+ pump inhibitors for the two major
Ca2+ pumps, respectively. The plasma membrane Ca2+ ATPase (PMCA) inhibitor, Caloxin
2A1, is a peptide (Val-Ser-Asn-Ser-Asn-Trp-Pro-Ser-Phe-Pro-Ser-Ser-Gly-Gly-Gly-NH2,
purchased from American Peptide Company) developed by using the phage display
technology.16–18 The specific inhibitor of the mitochondrial calcium uniporter, Ru360
(EMD Millipore), is a cell-permeable oxygen-bridged dinuclear ruthenium amine complex
that binds to mitochondria with a high affinity (Kd = 340 pM) and blocks Ca2+ uptake into
mitochondria at IC50 = 184 pM in vitro.19,20
H460 human lung cancer cells were pre-loaded with Fura-2 AM (Molecular Probes) using
the manufacturer’s protocol. After Fura-2 loading, H460 cells were treated with Ru360 at
~500 pM starting 30 min before the addition of LCP (2.5 mM as of calcium) and was
present throughout the whole ratio-imaging experiment. Divalent cation-free PBS was used
as the culture medium to avoid the interference of Ca2+ from the regular RPMI-1640
medium. Caloxin 2A1 at 1 mM was added 10 min before the addition of LCP and was
presented throughout the ratio imaging experiment. The live ratio images of the cells were
taken using an inverted Nikon ECLIPSE TE2000 microscope. This microscope was
designed with a rapid-switch excitation shutter, multifunction, time-lapse capabilities and
dual cameras that are ideal for Fura-2 experiment. A cell-culture chamber with temperature
(37 °C) and humidity (saturation) controls, as well as a 5% CO2 supply, was used to
maintain cell viability. We recorded ratio imaging for 10 sec, paused for the addition of
LCP, and then resumed recording for an additional 8 min.
During the ratio imaging, red pseudo-color was applied to the fluorescent signal when an
excitation of 380 nm was used. Green pseudo-color was applied when using 340 nm as the
excitation. Red and green images were then superimposed and adjusted to be in red color
before the addition of LCP (Figure 1). In the group without inhibitors some cells turned
green following the addition of LCP, indicating an elevated Ca2+ concentration in the
cytosol. Note that the cells were incubated with LCP throughout the imaging experiment.
The processes through which the cells took up LCP and pumped Ca2+ were both continuous.
As a result, some cells actually switched color several times during the observation period.
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As we hypothesized, when the Ca2+ pumps were inhibited, the cells lost their ability to cope
with the elevated cytosolic Ca2+ concentration. The cells turned green immediately and
rarely turned back to red. Furthermore, most cells started to lose their fluorescence,
indicating a loss of the Fura-2 dye. After imaging, we observed the morphology of the cells
using the phase contrast mode of the microscope. Most cells were swollen, which is a typical
sign of cell necrosis. Loss of cell membrane integrity is also a typical sign of necrosis. As
indicated in Figure 1, cells treated with only one inhibitor showed partial effects. PMCA
was more important in managing the Ca2+ toxicity caused by LCP; Caloxin 2A1 alone
seemed to have more effect than Ru360 alone (Figure 1). Empty DOTAP liposomes at the
same DOTAP concentration as was in LCP did not cause any color change (data not shown),
indicating that the observed change in Ca2+ concentration was not due to the cationic lipid.
Assuming X gram of tissue in vivo has a volume similar to that of the X mL of PBS used in
the in vitro experiment, i.e. the density of the tissue is approximately 1 g/mL, the
concentration of LCP used in this in vitro ratio-imaging experiment was calculated as ~50%
injected dose per gram tissue (ID/g) in the tumor after in vivo intravenous dosing. A
comparable accumulation level is rarely achievable in vivo. The H460 cells were exposed to
LCP as a single layer cell culture, which is also a condition not achievable in the tumor.
Thus, we conclude that the Ca2+ delivered by LCP is unlikely to cause apoptosis or necrosis
in vivo. Several in vivo studies delivering siRNA with the LCP formulation also reported
minimal toxicities in the animal models.2,3 Nevertheless, we have proceeded to test the
hypothesis in vivo.
Next, we tested the Ca2+ induced toxicity in vivo. Nude mice bearing H460 xenografts on
the right, hind leg were used. The two Ca2+ pump inhibitors together were administered
through intratumoral (IT) injection. The LCP NPs used in the in vivo experiment were
PEGylated. With DOTAP/Cholesterol as an outer leaflet, 15% DSPE-PEG2000 and 5%
DSPE-PEG2000-Anisamide (a targeting ligand for the sigma receptor)1 were added for
protection of the surface and enhancement of the cellular uptake by H460 tumor cells. The
PEGylated LCP NPs were ~25 nm in diameter and their zeta-potential was ~15 mV. The
mice were given LCP through either intravenous (IV) or IT injection. At 2 h post injection,
the mice were sacrificed and the tumors were fixed with formalin and sectioned for H&E
staining.
As Figure 2 indicates, there was no significant sign of necrosis in tumors that were not
treated, treated only with inhibitors or treated only with LCP delivered through IV injection.
Obvious cell necrosis was observed in tumors receiving an IT injection of inhibitors and
either an IV or IT injection of LCP. An additional mouse received an IT injection of both
inhibitors and LCP that was not PEGylated; this mouse exhibited the most severe necrosis in
the tumor (Figure 2F). PEGylation of LCP was necessary for IV injection; un-PEGylated
LCP did not accumulate in the tumor (data not shown). When administered through IT
injection, un-PEGylated LCP should interact more strongly with the tumor cells than the
PEGylated LCP. Thus, the result of the in vivo experiment confirmed our hypothesis that no
significant tumor cell necrosis can be induced by LCP unless the Ca2+ pumps of the tumor
cells are inhibited.
We conclude that in the normal condition, cells were able to manage the elevated cytosolic
Ca2+ delivered by LCP by removing the Ca2+ with two major Ca2+ pumps on the plasma
membrane and mitochondria, respectively (Figure 3). The elevated Ca2+ concentration was
only a transient event and was not toxic to the cells. Previous projects completed in this lab
regarding the delivery of siRNA to tumors and of genes to liver hepatocytes also indicated
that minimal toxicity existed in vivo.2,3 The current study has provided mechanistic insight
to these previous observations.
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PMCA Plasma membrane Ca2+ ATPase
MCU mitochondrial calcium uniporter
ER endoplasmic reticulum
MICU1 mitochondrial calcium-uptake 1
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Figure 1. Calcium pumps are important for Ca2+ toxicity management
Shown here are stills taken from the recorded video of H460 cells at the indicated time
points for four different treatment groups. Red color indicates low intracellular Ca2+
concentration under physiological conditions. Green color indicates elevated intracellular
Ca2+ concentration. Phase contrast images taken at 8 min are included to show round,
swollen cells.
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Figure 2. Tumor necrosis in vivo which has been induced by LCP with Ca2+ pump inhibitors
H460 subcutaneous tumor sections with H&E staining showing that LCP toxicity was only
observed in the presence of Ca2+ pump inhibitors. (A) Control H460 tumor without any
treatment. (B) Tumor that has received an IT injection of two Ca2+ pump inhibitors. (C)
Tumor that has received an IV injection of LCP. (D) Tumor that has received an IT injection
of two Ca2+ pump inhibitors and an IV injection of LCP. (E) Tumor that has received an IT
injection of two Ca2+ pump inhibitors and an IT injection of LCP. (F) Tumor that has
received an IT injection of two Ca2+ pump inhibitors and an IT injection of LCP without
PEGylation. Necrotic lesions were recognized as the “ghost” cells morphology on the H&E-
stained sections. Blue and black arrows indicate necrotic and severely necrotic regions,
respectively.
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Figure 3. Schematic illustration of the Ca2+ removing mechanism after LCP dosing
The elevated cytosolic Ca2+ delivered by LCP was rapidly removed by the PMCA on the
plasma membrane and the MCU on the mitochondria. Mitochondrial calcium-uptake 1
(MICU1) is a calcium sensor that regulates the Ca2+-influx capacity of MCU.
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